Not all sufferers with CLL need therapy. Despite all new improvements, the iwCLL nonetheless endorses watchful observation for sufferers with asymptomatic illness.86 This advice is based on at least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 Both of those trials concluded that https://edwinutqlg.life3dblog.com/31537105/link-alternatif-mbl77-an-overview